EUVIMEDEUVIMED entdecken
Crossref

Longitudinal Changes in Immune Biomarkers Following Direct‐Acting Antiviral Therapy in HIV/HCV‐Coinfected Individuals in Indonesia

Evy Yunihastuti, Youdiil Ophinni iD, Vidya Sari, Imam Adli, Chika Yamada, Alvina Widhani, Andri Sanityoso, Rino Alvani Gani

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Evy Yunihastuti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Hauptthemen laut MEDLINE: HIV Infections, Biomarkers, Antiviral Agents, Coinfection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: This study was funded by the Directorate of Research and Development at the University of Indonesia (PUTI Q1, grant number NKB-416/UN2.RST/HKP.05.00/2022) for…, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited evidence is available on the impact of direct‐acting antiviral (DAA) therapy on immune activation biomarkers in individuals coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study aimed to characterize longitudinal changes in soluble intercellular adhesion molecule‐1 (sICAM‐1), soluble β2‐microglobulin (sβ2M), and soluble CD14 (sCD14), following DAA treatment in an HIV/HCV‐coinfected cohort in Indonesia. A prospective study was conducted involving 132 HIV/HCV‐coinfected individuals treated with sofosbuvir/daclatasvir for 12 or 24 weeks. Plasma samples were collected at baseline and 12 weeks post‐DAA therapy. Levels of sICAM‐1, sβ2M, and sCD14 were quantified using enzyme‐linked immunosorbent assay (ELISA). Linear regression analyses were performed to identify predictors of biomarker changes. A sustained virological response was achieved in 96.2% of coinfected participants. At baseline, the HIV/HCV‐coinfected group exhibited significantly higher levels of sICAM‐1 and sCD14 compared to levels found in HIV monoinfection. At 12 weeks post‐treatment, significant reductions in sICAM‐1 ( p < 0.0002) and sβ2M levels ( p < 0.0002) were observed, irrespective of the baseline liver fibrosis stage. No significant change was noted in sCD14 levels. Notably, sICAM‐1 levels post‐treatment remained elevated compared to those in HIV monoinfection. Lower baseline serum albumin was an independent predictor of sβ2M reduction. DAA therapy was associated with significant reductions in sICAM‐1 and sβ2M levels among HIV/HCV‐coinfected individuals, irrespective of liver fibrosis stage. These findings highlight the immunomodulatory benefits of DAA therapy across different stages of liver disease in the Indonesian population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsBiomarkersAntiviral AgentsCoinfectionHepatitis C, ChronicHepatitis CHumansMaleFemaleIndonesiaAdultProspective StudiesMiddle AgedIntercellular Adhesion Molecule-1beta 2-MicroglobulinLipopolysaccharide ReceptorsLongitudinal StudiesCarbamatesSofosbuvirImidazolesPyrrolidinesValine

Stichwörter der Autor:innen

HIV/HCV coinfectiondaclatasvirdirect‐acting antiviralsimmune activationsCD14sICAM‐1sofosbuvirβ2‐microglobulin

Substanzen

BiomarkersAntiviral AgentsIntercellular Adhesion Molecule-1beta 2-MicroglobulinLipopolysaccharide ReceptorsCarbamatesSofosbuvirdaclatasvirImidazolesICAM1 protein, human

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • HIV Integrated Clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • The Hakubi Center for Advanced Research, Kyoto University, Kyoto, Japan.
  • Department of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan.
  • Division of Clinical Virology, Center for Infectious Diseases, Graduate School of Medicine, Kobe University, Kobe, Japan.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

ORCID-Profile: Youdiil Ophinni

Förderung

  • This study was funded by the Directorate of Research and Development at the University of Indonesia (PUTI Q1, grant number NKB-416/UN2.RST/HKP.05.00/2022) for…
  • Japan Society for the Promotion of Science

Zitieren

APA

Yunihastuti, E., Ophinni, Y., Sari, V., Adli, I., Yamada, C., Widhani, A., Sanityoso, A., & Gani, R. A. (2025). Longitudinal Changes in Immune Biomarkers Following Direct‐Acting Antiviral Therapy in HIV/HCV‐Coinfected Individuals in Indonesia. Journal of Medical Virology. https://doi.org/10.1002/jmv.70627

Vancouver

Yunihastuti E, Ophinni Y, Sari V, Adli I, Yamada C, Widhani A, et al. Longitudinal Changes in Immune Biomarkers Following Direct‐Acting Antiviral Therapy in HIV/HCV‐Coinfected Individuals in Indonesia. Journal of Medical Virology. 2025. doi:10.1002/jmv.70627

BibTeX
@article{Yunihastuti2025,
  author = {Yunihastuti, Evy and Ophinni, Youdiil and Sari, Vidya and Adli, Imam and Yamada, Chika and Widhani, Alvina and Sanityoso, Andri and Gani, Rino Alvani},
  title = {Longitudinal Changes in Immune Biomarkers Following Direct‐Acting Antiviral Therapy in HIV/HCV‐Coinfected Individuals in Indonesia},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70627}
}
Kostenlos starten →